MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, OPRX had $2,934K increase in cash & cash equivalents over the period. $3,192K in free cash flow.

Cash Flow Overview

Change in Cash
$2,934K
Free Cash flow
$3,192K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net income (loss)
779 -667
Depreciation and amortization
1,081 2,168
Stock-based compensation
1,956 3,046
Goodwill impairment
0 -
Bad debt expense
0 0
Amortization of debt issuance costs
174 611
Accounts receivable
-1,285 -4,700
Prepaid expenses and other assets
-510 958
Accounts payable
55 -174
Revenue share payable
-262 -2,462
Accrued expenses and other liabilities
-2,225 4,138
Operating lease liabilities
6 9
Deferred tax liabilities
-1,033 1,033
Taxes receivable and payable
-1,101 -964
Deferred revenue
-89 11
Net cash provided by operating activities
3,202 8,425
Purchase of property and equipment
10 37
Capitalized software development costs
0 91
Net cash used in investing activities
-10 -128
Cash paid for employee withholding taxes related to the vesting of restricted stock units
188 -
Proceeds from exercise of stock options
338 -
Repayment of long-term debt
500 5,000
Cash paid for employee withholding taxes related to the vesting of restricted stock units
-92
Net cash used in financing activities
-258 -5,092
Net increase in cash and cash equivalents
2,934 3,205
Cash and cash equivalents at beginning of period
13,380 -
Cash and cash equivalents at end of period
19,519 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

OptimizeRx Corp (OPRX)

OptimizeRx Corp (OPRX)